MB-Solutions is a developer and manufacturer of next generation of non-invasive diagnostic and therapeutic medical devices, utilizing patent-pending pulsed magnetic flux-field technologies to treat two pervasive medical ailments: (1) chronic and acute pain, and (2) heart disease.
New York (PRWEB) October 29, 2009 -- Mathematical Bio-Solutions Inc. (MB-Solutions) announced today that it has been selected in FundingPost's 6th annual Pitch Across America Competition as one of the Top 50 Emerging Companies of the FundingPost's Pitching Across America contest.
"We are proud to have MB-Solutions as one of this year's winners." said Joe Rubin, Director, FundingPost. "They have a quality product, led by a hard working and experienced management team. It's easy to see how they were chosen by our judges!"
MB-Solutions is a developer and manufacturer of next generation of non-invasive diagnostic and therapeutic medical devices, utilizing patent-pending pulsed magnetic flux-field technologies to treat two pervasive medical ailments. The initial such device, the Non-Invasive Pain Eliminator (NPE)TM provides long-term and permanent pain reduction and elimination. The NPE has clinically-proven effectiveness in curing various forms of chronic pain -- including arthritis -- injury-based and post-operative pain. The NPE pulsed magnetic field treatment method is a safe and effective non-invasive, alternative to pharmaceutical and surgical approaches to pain management, without risk of habituation or other adverse side effects.
"We are honored that FundingPost has named MB-Solutions as among the Top 50 emerging companies of Pitching Across America. As an early stage company, it's great to be so favorably recognized by a national panel of angel and venture capital investors. It certainly contributes additional validity to our business model and NPE technologies"--Steven Turner, Co-Founder of MB-Solutions
The next planned MB-Solutions device will similarly utilize pulsed magnetic field technologies, to address yet another pervasive medical ailment, heart disease: a completely External Cardiac Rhythm Normalizer (ECN)TM pacemaker. Successfully completed Phase I clinical trials confirm the potential of the ECN, once commercially-deployed emerging as a viable, cost-effective--and safer - alternative to surgically implanted pacemakers and defibrillators currently in use.
About FundingPost-With over 9,500 CEOs and 620 Venture Capital Funds attending events in 18 cities nationwide; a Printed Dealflow Magazine; and a deal-exchange website with over 7,500 VC & Angel Investor members & over 110,000 companies, that has, on average, made an introduction of an Investor to an Entrepreneur every business day since its inception; FundingPost believes that it is important to reach investors in every medium possible - both online and offline. FundingPost has been responsible for Millions and Millions of dollars in Venture Capital Raised! http://www.fundingpost.com
Contact: Steven M. Turner
135 W. 16th Street, Suite 11
New York, NY 10011
Read the full story at http://www.prweb.com/releases/2009/10/prweb3027864.htm.
Copyright©2009 Vocus, Inc.
All rights reserved